| Title |
EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma
|
|---|---|
| Published in |
OncoTargets and therapy, October 2015
|
| DOI | 10.2147/ott.s87146 |
| Pubmed ID | |
| Authors |
Yaoyao Ren, Yibing Yao, Qing Ma, Diansheng Zhong |
| Abstract |
The purpose of this study was to investigate the correlation between EGFR-mutation status and treatment efficacy for advanced lung adenocarcinoma patients. A total of 47 patients receiving erlotinib as first-line therapy were divided into two groups: the EGFR gene mutation group included 19 patients with known EGFR-sensitive mutations, and the EGFR-mutation status-unknown group comprised 28 patients with unknown EGFR-mutation status. Both objective response rate and disease-control rate were significantly higher in the EGFR-mutation group compared with the EGFR-unknown group (42.1% vs 14.2%, P=0.032; 94.7% vs 57.1%, P=0.005). Age, sex, smoking history, stage of disease, and tissue-sample source were not significantly correlated with the distributions of mutation status. In conclusion, it is important for advanced lung adenocarcinoma patients to undergo gene analysis before being assigned a molecularly targeted drug as first-line treatment. |
Mendeley readers
The data shown below were compiled from readership statistics for 9 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 2 | 22% |
| Researcher | 2 | 22% |
| Student > Bachelor | 1 | 11% |
| Unspecified | 1 | 11% |
| Student > Ph. D. Student | 1 | 11% |
| Other | 1 | 11% |
| Unknown | 1 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 33% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 11% |
| Unspecified | 1 | 11% |
| Agricultural and Biological Sciences | 1 | 11% |
| Biochemistry, Genetics and Molecular Biology | 1 | 11% |
| Other | 0 | 0% |
| Unknown | 2 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 21 October 2015.
All research outputs
#15,348,897
of 22,830,751 outputs
Outputs from OncoTargets and therapy
#1,027
of 2,933 outputs
Outputs of similar age
#160,897
of 274,926 outputs
Outputs of similar age from OncoTargets and therapy
#32
of 105 outputs
Altmetric has tracked 22,830,751 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,933 research outputs from this source. They receive a mean Attention Score of 2.6. This one has gotten more attention than average, scoring higher than 54% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 274,926 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 105 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.